查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1446557

心臟病學和神經病學 IVD 市場規模、佔有率和趨勢分析報告：按產品類型、技術、最終用途、地區和細分市場進行預測，2024-2030 年

IVD In Cardiology And Neurology Market Size, Share & Trends Analysis Report By Product Type (Instruments, Reagents & Consumables), By Technology, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

心臟病學和神經病學 IVD 市場的成長和趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球心臟和神經IVD市場規模將達到305.4億美元，2024年至2030年複合年成長率為9.44%。

市場成長的主要驅動力是由於老年人口的增加而導致心血管和神經病變的盛行率不斷增加。根據世界心臟聯盟發表的論文，2023年心血管疾病（CVD）將成為全球主要死亡原因，預計2021年將有2,050萬人死亡。此外，已發現神經系統疾病影響全球15%的人口。

將新藥或現有藥物與生物標記結合的創新治療方法不斷被公佈。例如，透過測量分子來追蹤大腦健康的生物標記現在被用於治療神經系統疾病。最近的生物標記進展，例如生物標記特徵，正在增強神經系統疾病的治療。其結果是早期診斷、快速藥物開發和非侵入性檢測。此外，數位生物標記為許多製藥公司提供了背景和補充訊息，以做出臨床試驗決策。例如，IXICO Plc 與領先的生物製藥公司合作，對數位生物標記進行臨床驗證並將其用於臨床試驗。

此外，用於診斷 AD 和輕度創傷性腦損傷等適應症的 BBBM 測試的開發和推出也促進了市場的成長。例如，2020 年 3 月，NIH 資助的研究人員開發了一種基於血液的測試，可以檢測磷酸化Tau -181 (ptau181)，這表阿茲海默症的存在。與現有的腦部影像檢查和腦脊髓液測試相比，這種方法成本更低，侵入性也更低。同樣，2021 年 1 月，雅培推出了首個針對創傷性腦損傷（包括腦震盪）的快速血液檢測。此測試可測量腦外傷後血液中的某些蛋白質，如果測試結果為陰性，可用於排除電腦斷層掃描的必要性。

此外，IVD 在診斷和監測各種疾病的各個臨床領域中變得越來越重要。增加針對心血管和神經系統疾病的新型 IVD 解決方案的可用性是預計推動市場成長的關鍵因素之一。例如，2023年10月，邁瑞宣布擴大心臟生物標記產品組合，推出兩種新型高靈敏度NT-proBNP和肌鈣蛋白i (hs-cTnI)心臟生物標記。透過此次推出，該公司旨在透過創新技術加強現有產品組合併使其多樣化，以更好地診斷和管理 CVD。此外，2023 年 7 月，Quest Diagnostics 宣布推出阿茲海默症AD-Detect 測試，這是第一個幫助人們了解阿茲海默症症潛在風險的消費者測試。

心臟病學和神經病學 IVD 市場報告亮點

  • 試劑和耗材領域預計將引領市場，並在 2024 年至 2030 年實現最快的複合年成長率。這是由於領先公司為開發新型生物標記套件而進行的廣泛研究和開發舉措。
  • 由於新型免疫診斷解決方案的研發不斷增加，免疫測量領域在 2023 年引領市場。
  • 由於先進和創新的分子診斷儀器的發展，分子診斷領域預計將從 2024 年到 2030 年以最快的複合年成長率成長。
  • 由於領先的醫療機構提供優質醫療保健以向醫院提供創新設備的總體趨勢，醫院最終用途細分市場將在 2023 年引領市場。
  • 由於先進的醫療基礎設施、目標疾病盛行率上升以及有利的法規環境等因素，北美在2023年將主導全球市場。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章心臟病學和神經病學 IVD 市場：變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 心臟病學和神經病學 IVD 市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 價格分析
    • 體積分析（設備）

第4章心臟病和神經病學IVD市場：產品類型估算和趨勢分析

  • 全球心臟病學和神經學 IVD 市場：產品類型儀表板
  • 心臟病學和神經病學 IVD 的全球市場：產品類型變化分析
  • 全球心臟病學/神經學 IVD 市場，按產品類型分類的收益
  • 裝置
  • 試劑/耗材
  • 軟體服務

第5章心臟病和神經病學IVD市場：技術評估和趨勢分析

  • 全球心臟病學和神經病學 IVD 市場：技術儀表板
  • 心臟病學和神經病學 IVD 的全球市場：技術波動分析
  • 全球心臟病學和神經病學 IVD 市場（按技術和收益分類）
  • 免疫測量
  • 分子診斷
  • 血
  • 其他

第6章心臟病學和神經病學的 IVD 市場：最終用途估計和趨勢分析

  • 全球心臟病學和神經病學 IVD 市場：最終用途儀表板
  • 全球心臟病學和神經病學 IVD 市場：最終用途變化分析
  • 全球心臟病學/神經學 IVD 市場，按最終用途、收益
  • 醫院
  • 臨床實驗室
  • 其他

第 7 章 心臟病學和神經病學 IVD 市場：區域估計和趨勢分析，按產品類型、技術、最終用途

  • 區域儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商形勢
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd
    • Sysmex Corporation
    • Siemens Healthineers AG
    • Quest Diagnostics Incorporated
    • Abbott
    • BD（Becton Dickinson）
    • Bio-Rad Laboratories, Inc.
    • Beckman Coulter, Inc.
Product Code: GVR-4-68040-204-5

IVD In Cardiology And Neurology Market Growth & Trends:

The global IVD in cardiology and neurology market size is anticipated to reach USD 30.54 billion by 2030, registering a CAGR of 9.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is primarily driven by the increasing prevalence of cardiovascular and neurological disorders aided by the growing geriatric population. According to an article published by the World Heart Federation, in 2023, cardiovascular diseases (CVDs) are the leading cause of death worldwide, with an estimated deaths registered being 20.5 million in 2021. Moreover, neurological disorders are found to affect 15% of the total population globally.

Innovative treatments that combine new or existing medicines with biomarkers are continuously being launched. For instance, currently, biomarkers are used for the treatment of neurological diseases to track brain health by measuring molecules. Recent progressions in biomarkers, such as biomarker signatures, are enhancing the treatment of neurological diseases. This has resulted in early diagnosis, faster drug development, and noninvasive testing. Moreover, digital biomarkers offer numerous pharmaceutical companies contextual and supplemental information to conclude clinical trial decisions. For instance, IXICO Plc is collaborating with major biopharmaceutical firms to authenticate clinically digital biomarkers and use them in clinical trials.

Moreover, the development and introduction of BBBM tests for the diagnosis of indications, such as AD & mild traumatic brain injury, among others, are contributing to market growth. For instance, in March 2020, NIH-funded researchers developed a blood-based test for detecting phosphorylated-tau-181 (ptau181), indicating Alzheimer's disease presence. This approach is less costly and invasive than the existing brain imaging & spinal fluid tests. Similarly, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.

Furthermore, IVDs are gaining increasing importance across various clinical fields for the diagnosis and monitoring of various diseases. A rise in the availability of novel IVD solutions for cardiovascular and neurological disorders is one of the major drivers anticipated to boost market growth. For instance, in October 2023, Mindray announced the expansion of its cardiac biomarker portfolio with the launch of two novel highly sensitive NT-proBNP and troponin I (hs-cTnI) cardiac biomarkers. With this launch, the company aims to enhance and diversify its existing portfolio with innovative technologies for better diagnosis and management of CVDs. Moreover, in July 2023, Quest Diagnostics announced the availability of the first test available for consumers, the AD-Detect Test for Alzheimer's Disease that helps in accessing the potential risk of developing Alzheimer's disease.

IVD In Cardiology And Neurology Market Report Highlights:

  • The reagents & consumables segment led the market and is anticipated to register the fastest CAGR from 2024 to 2030 owing to extensive R&D initiatives being undertaken by major players for the development of novel biomarker kits
  • The immunoassays segment led the market in 2023 due to the rising R&D about the development of novel immunological diagnostic solutions
  • The molecular diagnostic segment is anticipated to grow at the fastest CAGR from 2024 to 2030 owing to the development of advanced and innovative molecular diagnostics instruments
  • The hospitals end-use segment led the market in 2023 due to the popular trend of providing innovative devices in hospitals by key plato provideiding quality care
  • North America dominated the global market in 2023 owing to factors, such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Type
    • 1.2.2. Technology
    • 1.2.3. End-use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product type and technology outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of chronic diseases such as cardiovascular and neurological disorders
      • 3.2.1.2. Technological advancement
      • 3.2.1.3. Increasing demand for point-of-care diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of devices
      • 3.2.2.2. Stringent regulatory policies
  • 3.3. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Volume Analysis (Instruments)

Chapter 4. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Product Type Estimates & Trend Analysis

  • 4.1. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Product Type Dashboard
  • 4.2. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Product Type Movement Analysis
  • 4.3. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market by Product Type, Revenue
  • 4.4. Instruments
    • 4.4.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Reagents & Consumables
    • 4.5.1. Reagents & consumables market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Software and Services
    • 4.6.1. Software and services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Technology Estimates & Trend Analysis

  • 5.1. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Technology Dashboard
  • 5.2. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Technology Movement Analysis
  • 5.3. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market by Technology, Revenue
  • 5.4. Immunoassays
    • 5.4.1. Immunoassays market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Molecular Diagnostics
    • 5.5.1. Molecular diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Hematology
    • 5.6.1. Hematology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: End-use Estimates & Trend Analysis

  • 6.1. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: End-use Dashboard
  • 6.2. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: End-use Movement Analysis
  • 6.3. Global In Vitro Diagnostics (IVD) in Cardiology and Neurology Market by End-use, Revenue
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Clinical Laboratories
    • 6.5.1. Clinical laboratories market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. In Vitro Diagnostics (IVD) in Cardiology and Neurology Market: Regional Estimates & Trend Analysis by Product Type, Technology, and End-use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Thermo Fisher Scientific Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. F. Hoffmann-La Roche Ltd
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Sysmex Corporation
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Siemens Healthineers AG
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Quest Diagnostics Incorporated
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Abbott
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. BD (Becton Dickinson)
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Bio-Rad Laboratories, Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Beckman Coulter, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 4 North America in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 5 North America in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 U.S. in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 7 U.S. in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 8 U.S. in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 10 Canada in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 11 Canada in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 14 Europe in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 15 Europe in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Germany in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 17 Germany in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 18 Germany in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 UK in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 20 UK in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 21 UK in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 France in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 23 France in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 24 France in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Italy in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 26 Italy in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Italy in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Spain in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 29 Spain in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 30 Spain in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Denmark in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 32 Denmark in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 33 Denmark in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Sweden in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 35 Sweden in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 36 Sweden in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Norway in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 38 Norway in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 39 Norway in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 43 Aisa Pacific in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 China in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 45 China in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 46 China in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Japan in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 48 Japan in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 49 Japan in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 51 India in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 52 India in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 South Korea in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 54 South Korea in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 55 South Korea in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Australia in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 57 Australia in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 58 Australia in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Thailand in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 60 Thailand in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 61 Thailand in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 64 Latin America in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 65 Latin America in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Brazil in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 67 Brazil in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 68 Brazil in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Mexico in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 70 Mexico in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 71 Mexico in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 72 Argentina in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 73 Argentina in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 74 Argentina in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 MEA in vitro diagnostics (IVD) in cardiology and neurology market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 77 MEA in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 78 MEA in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 79 South Africa in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 80 South Africa in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 81 South Africa in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 UAE in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 86 UAE in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 87 UAE in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait in vitro diagnostics (IVD) in cardiology and neurology market, by product type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait in vitro diagnostics (IVD) in cardiology and neurology market, by technology, 2018 - 2030 (USD Million)
  • Table 90 Kuwait in vitro diagnostics (IVD) in cardiology and neurology market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 In vitro diagnostics (IVD) in cardiology and neurology market: market outlook
  • Fig. 14 In vitro diagnostics (IVD) in cardiology and neurology competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 In vitro diagnostics (IVD) in cardiology and neurology market driver impact
  • Fig. 18 In vitro diagnostics (IVD) in cardiology and neurology market restraint impact
  • Fig. 19 In vitro diagnostics (IVD) in cardiology and neurology market: Product type movement analysis
  • Fig. 20 In vitro diagnostics (IVD) in cardiology and neurology market: Product type outlook and key takeaways
  • Fig. 21 Instruments market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Reagents & consumables estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Software and services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 In vitro diagnostics (IVD) in cardiology and neurology market: Technology movement analysis
  • Fig. 25 In vitro diagnostics (IVD) in cardiology and neurology market: Technology outlook and key takeaways
  • Fig. 26 Immunoassays market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Molecular diagnostics estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Hematology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 In vitro diagnostics (IVD) in cardiology and neurology market: End-use movement analysis
  • Fig. 31 In vitro diagnostics (IVD) in cardiology and neurology market: End-use outlook and key takeaways
  • Fig. 32 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Clinical laboratories estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Global in vitro diagnostics (IVD) in cardiology and neurology market: Regional movement analysis
  • Fig. 36 Global in vitro diagnostics (IVD) in cardiology and neurology market: Regional outlook and key takeaways
  • Fig. 37 Global in vitro diagnostics (IVD) in cardiology and neurology market share and leading players
  • Fig. 38 North America, by country
  • Fig. 39 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. key country dynamics
  • Fig. 41 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Canada key country dynamics
  • Fig. 43 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK key country dynamics
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany key country dynamics
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 France key country dynamics
  • Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 China key country dynamics
  • Fig. 63 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Japan key country dynamics
  • Fig. 65 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 India key country dynamics
  • Fig. 67 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand key country dynamics
  • Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea key country dynamics
  • Fig. 71 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Australia key country dynamics
  • Fig. 73 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Brazil key country dynamics
  • Fig. 76 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Mexico key country dynamics
  • Fig. 78 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Argentina key country dynamics
  • Fig. 80 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 South Africa key country dynamics
  • Fig. 83 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Saudi Arabia key country dynamics
  • Fig. 85 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 UAE key country dynamics
  • Fig. 87 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Kuwait key country dynamics
  • Fig. 89 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Market share of key market players- In vitro diagnostics (IVD) in cardiology and neurology market